It is well known that platelet activation plays a key role in the pathogenesis of acute coronary syndromes (ACS) and acute ischemic stroke (AIS). Thus, a novel platelet-associated vascular endothelium secreted protein, plasma, SCUBEl (endothelial growth factor-like single chain protein 1-related complement Clr / Cls) is associated with platelet activation. Analysis of the clinical significance of platelet activation markers, plasma SCUBEl, in the presence of ACS and AIS.
Forty patients with ACS and AIS were enrolled in the study. Forty patients and 83 patients with stable coronary artery disease (CAD) were selected as the control group. The patients were divided into 1 group (n = Group and 4 healthy controls. Are in the early removal of cardiomyopathy, severe valvular disease, cancer, blood or rheumatism, liver Renal insufficiency after the study.The levels of plasma SCUBEl were measured by enzyme-linked immunosorbent assay (ELISA), and the difference of plasma SCUBEl between the four groups was observed and analyzed. The clinical significance of plasma SCUBEl elevation was also observed.
The results showed that there was no significant difference in age, sex and blood platelet count between the four groups, and the risk factors of cardiovascular disease were significantly higher in group 1, 2 and 3 than in 4 groups. Comparative analysis showed that the levels of plasma SCUBE1 were significantly higher in the two groups than in the two groups (205 vs 95.1 ng / mL: 50 vs <50 ng / mL, P <0.01), and only two or two groups of SCUBEl The mean was significantly increased, especially in the two groups increased significantly in the elderly. The mean value of plasma SCUBEl was increased from 6 months after onset of ACS and AIS, and continued to rise to 84 h after the disease. The peak period was 36 ~ 60 h after the disease and 96 h after the disease reduce. Multivariate analysis showed that elevated plasma SCUBEl could independently predict the severity of AIS (P <0.001), although it was not associated with plasma cardiac troponin levels in both groups, but higher plasma was observed in both groups SCUBEl fragment, suggesting that plasma SCUBEl may be at least partially hydrolyzed.
The results of this paper suggest that plasma SCUBEl levels will be significantly increased regardless of ACS or AIS patients, rather than stable CAD patients. Indicating that only in the acute thrombosis period, plasma SCUBEl is one of the strong markers of platelet activation.